Bexsero Efficacy and Dosing Intervals in Infants Under 12 Months
Critical Limitation: No U.S. Recommendations for This Age Group
Bexsero is not licensed or recommended for use in infants under 12 months of age in the United States. The FDA has authorized Bexsero only for individuals aged 10-25 years, and the CDC/ACIP has issued no recommendations for MenB vaccines in children younger than 10 years 1, 2, 3. Any use in infants would be considered off-label and outside current U.S. guidelines 2.
Evidence from International Programs (Where Infant Use Is Approved)
While U.S. guidelines do not address infant vaccination with Bexsero, international data from countries that do vaccinate infants provides relevant immunogenicity and effectiveness information:
Impact of Dosing Intervals on Protection
Shorter intervals between doses may provide earlier protection without compromising efficacy, which is critical given the high disease burden in early infancy.
In England's national infant immunization program (which uses a 2+1 schedule at 8 weeks, 16 weeks, and 12 months), research demonstrated that a schedule with doses at 8 and 12 weeks (4-week interval) had the potential to offer protection to 58.6% more infants who developed MenB disease between 10-18 weeks of age compared to the current 8 and 16-week schedule 4.
The study identified that 46.5% of infants eligible for two doses and 36.6% of children aged ≥1 year had missed vaccination opportunities before developing MenB disease, emphasizing that timely vaccination is critical because of the high incidence in early childhood 4.
After England's 4CMenB implementation, the peak age of MenB disease shifted from 5-6 months to 1-3 months, with 35% of cases occurring in infants younger than 3 months who were too young for vaccination 5. This highlights that earlier vaccination schedules could theoretically protect more infants during the highest-risk period.
Immunogenicity with Different Infant Schedules
Clinical trials demonstrated that the majority of vaccine-naive infants achieved seroprotective antibody titers after three doses administered at either 2,3, and 4 months OR 2,4, and 6 months of age 6. This indicates that both 1-month and 2-month intervals between doses in the primary series generate robust immune responses.
A 4-week minimum interval between any two doses of Bexsero is acceptable based on current FDA labeling 3, though this applies to the approved age groups (10-25 years).
Real-World Effectiveness Data
A Spanish case-control study (where 4CMenB was available for private purchase starting in 2015) found complete vaccination effectiveness of 76% against invasive meningococcal disease caused by any serogroup and 71% against serogroup B disease specifically in children under 5 years 7.
Partial vaccination (at least one dose) showed 54% effectiveness, indicating that even incomplete series provide meaningful protection 7.
Among 44 serogroup B strains expected to be covered by 4CMenB, none occurred in vaccinated children, demonstrating strong real-world protection when the vaccine is administered 7.
Clinical Implications for U.S. Practice
What This Means for Providers
Do not administer Bexsero to infants under 10 years of age in routine U.S. practice 1, 2, 3. The vaccine should only be considered starting at age 10 years for high-risk individuals (complement deficiency, asplenia, microbiologist exposure, outbreak settings) 1, 3.
For high-risk patients aged ≥10 years, use the 3-dose schedule at 0,1-2, and 6 months 1, 3, 8. The updated 2024 FDA label and ACIP recommendations now align Bexsero dosing with the other MenB vaccine (Trumenba) 8.
The minimum interval between any two doses is 4 weeks, though the recommended schedule spaces doses further apart for optimal immunogenicity 3, 8.
Important Caveats
Bexsero and Trumenba are not interchangeable—the same product must be used for all doses in the series, including boosters 1, 3, 8.
Premature birth is a precaution for MenACWY-CRM vaccine (not Bexsero, but a different meningococcal vaccine) due to post-vaccination apnea risk 2. While this doesn't directly apply to Bexsero in the U.S. context (since it's not used in infants), it underscores the need for caution with meningococcal vaccines in very young or premature infants.
International data suggests that extending intervals does not reduce efficacy and may improve immune responses (as seen with the updated 0 and 6-month schedule for healthy adolescents) 8, but shorter intervals can provide earlier protection when disease risk is highest 4.
Bottom Line
In the United States, questions about Bexsero dosing intervals in infants under 12 months are not clinically relevant because the vaccine is neither licensed nor recommended for this age group. International evidence demonstrates that both shorter (1-month) and longer (2-month) intervals between infant doses generate protective immune responses, with shorter intervals potentially offering earlier protection during the highest-risk period of early infancy 4, 6, 5. However, U.S. providers should only consider Bexsero starting at age 10 years for high-risk populations, using the 3-dose schedule at 0,1-2, and 6 months 1, 3, 8.